On the prediction of Hodgkin lymphoma treatment response
نویسندگان
چکیده
منابع مشابه
Hodgkin Lymphoma and Anaplastic Variants of Non-Hodgkin Lymphoma
Background and Objectives: Classic Hodgkin lymphoma (CHL), anaplastic large cell lymphoma (ALCL) and some cases of diffuse large B cell lymphoma (DLBCL) have overlapping morphologic features. Since they all represent distinct clinico-pathologic entities, we explored the differential diagnostic impact of immunophenotyping to discriminate between them. Materials and Methods:...
متن کاملTreatment of Newly Diagnosed and Relapsed Hodgkin Lymphoma in Children
Hodgkin lymphoma (HL) accounts for about 10% of all childhood cancers. Five-year survival rates with modern therapies are now approaching >90-95% as a consequence of its significant sensitivity to both chemotherapy and radiation. The current challenge is to determine how much therapy is needed to improve survival and how to adapt treatment to the patient to prevent these long term toxicities. T...
متن کاملTreatment of early-stage Hodgkin lymphoma.
Hodgkin lymphoma (HL) has become one of the best curable malignancies today. This is particularly true for patients with early-stage disease. Today, most patients in this risk group are treated with a combination of chemotherapy followed by small-field radiotherapy. More recent clinical trials such as the German Hodgkin Study Group (GHSG) HD10 study demonstrated, that even two cycles of ABVD fo...
متن کاملTreatment of lymphocyte-predominant Hodgkin lymphoma.
Lymphocyte-predominant Hodgkin lymphoma (LPHL) was first described as Hodgkin’s paragranuloma by Jackson and Parker in 1944 [1]. Subsequently, a number of different terms such as lymphocytic-predominant Hodgkin’s disease or lymphocytic and histiocytic-predominant Hodgkin’s disease were used [2]. LPHL is rare, accounting for 5% of all Hodgkin lymphoma (HL) cases in western countries [3]. LPHL an...
متن کاملTreatment of Early Stage Hodgkin Lymphoma
Hodgkin lymphoma (HL) is an uncommon lymphoid malignancy which accounts for about 0.5% to 1% of all cancers. In 2010, an estimated 8,490 new cases and 1,320 deaths will occur in the United States (Jemal, Siegel, Xu, et al, 2010). HL incidence appears to be stable over the past few decades, in contrast to the incompletely understood continued increase in frequency of non-Hodgkin lymphomas. HL ha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical and Translational Oncology
سال: 2015
ISSN: 1699-048X,1699-3055
DOI: 10.1007/s12094-015-1285-z